{
    "clinical_study": {
        "@rank": "127655", 
        "acronym": "HA-PCI vs PCI", 
        "arm_group": [
            {
                "arm_group_label": "Prophylactic Cranial Irradiation", 
                "arm_group_type": "Active Comparator", 
                "description": "Radiation. Prophylactic Cranial Irradiation: 10 times 2.5 Gy (total 25 Gy)"
            }, 
            {
                "arm_group_label": "Hippocampal Avoidance PCI", 
                "arm_group_type": "Experimental", 
                "description": "Radiation. Hippocampal Avoidance PCI. 10 times 2.5 Gy (total 25 Gy)."
            }
        ], 
        "brief_summary": {
            "textblock": "Using Intensity Modulated radiotherapy it is possible to treat the entire brain to standard\n      dosages of whole-brain radiation, while keeping the radiation dose to the hippocampus low.\n      However, a clear relationship between radiation dose and damage to the hippocampal stem\n      cells has not been established yet.\n\n      This study is initiated to investigate the early and delayed neurotoxicity of PCI and to\n      assess in a randomised design the benefits and risks of sparing the hippocampus in Small\n      Cell Lung Cancer patients who receive PCI."
        }, 
        "brief_title": "Hippocampus Avoidance PCI vs PCI", 
        "completion_date": {
            "#text": "June 2021", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Small Cell Lung Cancer", 
            "Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2212 Small Cell Lung Cancer patients (stage I-III or stage IV without clinical or\n             radiological evidence of brain metastases) candidate for PCI, i.e. without\n             progressive disease after chemo-radiotherapy in stage I-III or after a remission\n             after chemotherapy in stage IV\n\n               -  Sufficient proficiency in Dutch\n\n        Exclusion Criteria:\n\n          -  Prior radiotherapy to the brain\n\n          -  Clinical evidence for brain metastases or primary brain tumors\u2212 Evidence of\n             progressive extracranial metastatic disease\n\n          -  Previous malignancy < 2 years ago except for adequately treated basal cell carcinoma\n             of the skin and carcinoma in situ of the cervix\n\n          -  Any systemic anticancer treatment during PCI or within 3 weeks before start PCI\n\n          -  Pregnancy or lactation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "168", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780675", 
            "org_study_id": "M12PHA", 
            "secondary_id": "unknown"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prophylactic Cranial Irradiation", 
                "intervention_name": "Radiation Prophylactic Cranial Irradiation", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Hippocampal Avoidance PCI", 
                "intervention_name": "Radiation Hippocampal Avoidance PCI", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prophylactic Cranial Irradiation", 
            "Hippocampal Avoidance Prophylactic Cranial Irradiation"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "location": [
            {
                "contact": {
                    "email": "j.belderbos@nki.nl", 
                    "last_name": "Jose Belderbos, MD, PhD", 
                    "phone": "+31 20 512 2135"
                }, 
                "contact_backup": {
                    "email": "s.schagen@nki.nl", 
                    "last_name": "Sanne Schagen, PhD", 
                    "phone": "+31 20 512 2328"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066CX"
                    }, 
                    "name": "The Netherlands Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Jose Belderbos, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "katrien.d.jaeger@catharinaziekenhuis.nl", 
                    "last_name": "Katrien de Jaeger, MD, PhD", 
                    "phone": "+31 40 239 6400"
                }, 
                "facility": {
                    "address": {
                        "city": "Eindhoven", 
                        "country": "Netherlands", 
                        "zip": "5623EJ"
                    }, 
                    "name": "Catharina Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "Katrien de Jaeger, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial", 
        "overall_contact": {
            "email": "j.belderbos@nki.nl", 
            "last_name": "Jose Belderbos, MD, PhD", 
            "phone": "+31 20 512 2174"
        }, 
        "overall_contact_backup": {
            "email": "s.schagen@nki.nl", 
            "last_name": "Sanne Schagen, PhD", 
            "phone": "+ 31 20 512 2328"
        }, 
        "overall_official": {
            "affiliation": "The Netherlands Cancer Institute", 
            "last_name": "Jose Belderbos, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Each patient's total recall score recorded at 4 months will be compared to baseline and dichotomized into success (decline less or equal 5 points) or failure (decline more than 5 points). The difference between the groups, in terms of dichotomized decline will be tested by means of the Fisher's exact test. A p-value less than 0.049 will be considered significant. The primary analysis will be based on an intention-to-treat principle.", 
            "measure": "neurocognitive decline", 
            "safety_issue": "Yes", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780675"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Brain metastases Time from randomization to the occurrence of brain metastases will be calculated and depicted in a cumulative incidence plot. Sensitivity analysis will be performed to assess the value of PCI vs HA-PCI treatment once considering patients dying without distant brain metastases to be censored and once using competing risk analysis considering distant metastases and death as separate events", 
            "measure": "safety", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "The Netherlands Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Dutch Cancer Society", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "The Netherlands Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}